Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Cream, (US RLD-Temovate Cream), 0.05%. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

The group now has 222 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 4.25, or 1.12%, to trade at Rs 376.50. The total volume of shares traded was 113,349 at the BSE (3.10 p.m., Wednesday).